Key challenges and priorities in sales transformation indonesia prespective
SANOFI_Presentation_EN
1. CORPORATE PRESENTATION 2011 1
Corporate Presentation
SANOFIA global healthcare leader,
focused on patients’ needs
2. A global healthcare leader,
focused on patients’ needs
2
world’s largest
pharmaceutical
groups
1 employees in
110,000€30.43.7% (1) growth in
net sales for 2010
billion
(1) a reported basis
countries100
CORPORATE PRESENTATION 2011
of the
Source : 20F Form 2010, employees estimation march 2011, annual review 2010
3. 1973 to 2008 2009 to 2011
300mergers and acquisitions
Diversified Healthcare Leader
10 110,000Employees
Health, Beauty, Nutrition
Evolution
3CORPORATE PRESENTATION 2011
Acquired companies including Genzyme
+61in-licensing agreements
+2joint ventures
Invested a total of ~ €23bnin external growth
23
Source: employees estimation march 2011, IR presentation September 6, 2011
5. Our commitment
5
Sanofi is more than
a pharmaceutical laboratory;
We act with our partners to protect
health, enhance life and respond
to the potential healthcare needs of
the 7 billion people around the world
we are a diversified healthcare company
CORPORATE PRESENTATION 2011
6. Our ambition
6
We demonstrate
leadership both
in business
achievements and
in the communities
in which we operate
We are a global
healthcare leader,
focused on
patients’ needs
We wish to be known
for our ability
to transform
scientific innovations
into therapeutic
solutions for patients
CORPORATE PRESENTATION 2011
7. Our global presence
7
(1) US + Canada + Porto Rico
(2) Western Europe + Eastern Europe + Turkey
(3) Australia + New Zealand
Africa, Middle East
€846 M
€789 M
Employees
Sales Africa
Europe (2)
€11,609 M
Employees
Sales
North America (1)
€9,484 M
+15,000
Sales
Employees
South America
€2,735 M
9,000
Sales
Employees
Japan
€2,225 M
Employees
Sales
Asia, Pacific (3)
€1,983 M
€713 M
Sales Asia
Employees+4,500
55,000 +3,000
+15,000
Sales
Middle East
Sales
Pacific
CORPORATE PRESENTATION 2011
Source: Solid results in 2010, press release Febuary 9th 2011
9. Accelerate innovation for patients
9
1. INCREASE INNOVATION IN R&D
Sanofi R&D
A new R&D model to
improve health worldwide
and bring therapeutic
solutions to patients:
• Simplification
• Openness
• Partnerships
• Biotechnologies
Priorities
Diabetes
Fibrosis and tissue repair
Immuno-inflammation
Infectious diseases
Rare diseases
Oncology
Ophthalmology
Aging
R&D Portfolio
Q2 results 2011
molecules
and vaccines
65
2012 - 2015
19 potential new launches*
CORPORATE PRESENTATION 2011
Source: IR presentation September 6, 2011
10. Develop innovative health solutions
10
1. INCREASE INNOVATION IN R&D
Dengue vaccine
Note : LemtradaTM (alemtuzumab), AubagioTM (teriflunomide) and Lyxumia® (lixisenatide) are brand names for projects currently in development for which all necessary regulatory authorizations
have not been attained.
(1) Licensed by Zealand Pharma A/S, expected regulatory submission in EU Q4 2011 and US Q4 2012
(2) expected regulatory submission in MS in US and EU Q1 2012
(3) filed in the US in Q3 2011 and expected regulatory submission in EU Q1 2012)
(1)
CORPORATE PRESENTATION 2011
(2014)
Oncology Diabetes Vaccines
Multiple sclerosis Biosurgey renal
Source: IR presentation September 6, 2011
(2)
(3)
11. Strengthen our activities through external growth
11
2. SEIZE EXTERNAL GROWTH OPPORTUNITIES
Generics
Human
vaccines
Consumer
healthcare
Diabetes
Rare
diseases
Innovative
products
Animal
health
CORPORATE PRESENTATION 2011
REGULUS
acquisitions
and partnerships
In 2009
acquisitions
and partnerships
In 2010
33
37
Source : annual review 2009 and 2010
12. Growth platforms: 57% of sales in 2010 (1)
12
3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES
Emerging markets
Human vaccines
Consumer healthcare
Diabetes solutions
Innovative products
Animal health
CORPORATE PRESENTATION 2011
Source: IR presentation September 6, 2011
(1) Including sales of merial
13. Emerging markets(1): a new world vision
13
Brazil
China
Russia
+51.4% (2)
+23.6% (2)
+19.9%(2)
Sales Split (%):
Results
#1
#3
#2
(1) The World less the United States, Canada, Western Europe, Japan, Australia and New Zealand.
Organic growth in emerging markets: + 13.2% in 2010.
(2) At constant exchange rates.
(3) RoW: Japan, Australia, New Zealand, Canada
CORPORATE PRESENTATION 2011
+16.3 %(2)
3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES
30.4 %
12.2 %
28.5 %
28.9 %
U.S.
RoW (3)
Emerging
Markets
Western
Europe
local production sites
support market access
38
employees
40,000
Nearly
Source : annual review 2010, presentation of Q2 2011 Results, IR presentation September 6, 2011
14. Human vaccines: Sanofi Pasteur, a world leader
14
Dengue vaccine
Clostridium difficile
vaccine
(1) Growth at constant exchange rates
3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES
Leadership position
in pediatrics, flu, meningitis,
travel & endemics
Broad Product Offering
Sales Split 2011e
Flu Polio /
Pertussis /
Hib
Boosters
Other 6%
12%
11%
27%
13%
31%
Meningitis /
PneumoTravel /
Endemics
Today
Tomorrow €3.8 bn
+4.8%
(1)
consolidated
sales in 2010
doses of seasonal influenza
vaccine distributed
worldwide
198,000,000
In 2010
12.5 %
Vaccines for
20
infectious diseases
CORPORATE PRESENTATION 2011
of Sanofi sales
Source : annual rewiew 2010, presentation General meeting 2011 May 6, 2011, IR presentation September 6, 2011
15. Consumer healthcare: diversification and strong growth
15
Keys legacy brands
In March 2011
Launch
of Allegra®
over the counter
in the US
€2,2
(1) Includes Chattem sales since 10 February 2010
+6.9% in 2010 on a constant structure basis ant at constant exchange rates
3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES
bn
2010 Sales: +45.7 %(1)
Sanofi has become
a global player (2)
#1in Latin America,
in Australia
#3
in Russia,
in Central
& Eastern Europe
Scaling up
in China and Asia
Among top 10 in U.S (3)
CORPORATE PRESENTATION 2011
(2) Nicolas Hall, OTC Yearbook, 2011, DBG 2011 (2011 Sales)
(3) Including Allegra® OTC sales in 2011, internal estimates
Source : annual rewiew 2010, IR presentation September 6, 2011
16. Diabetes solutions
16
Lantus®
Amaryl®
Apidra®
BGStar® and iBGStar®
BGStar® and iBGStar®
Integrate BGM
and Lantus® dosing
device Lyxumia®
(lixisenatide)
Type 2 diabetes
Lantus® in 2010
120,000,000Lantus® and SoloSTAR®
pens sold
insulin brand name
worldwide
+9.2%(1)
14.1% of Sanofi sales #1
#1
€3.5 bn
diabetes treatment
with sales of
Today
Tomorrow
€4,3 bn
CORPORATE PRESENTATION 2011
3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES
(1) Growth at constant exchange rates
Source : annual rewiew 2010, presentation General meeting 2011 May 6, 2011, IR presentation September 6, 2011
17. Innovative products: bringing new hope
17
Kynamro™ (mipomersen)
hoFH(1) and
Severe heFH(2)
Visamerin®
Mulsevo® (semuloparin)
VTE(3) prevention in
chemo-treated patients
Aubagio™ (Teriflunomide) RMS(4)
Zaltrap™ (Aflibercept) 2L-mCRC(5)
Lyxumia® (lixisenatide) Type 2 diabetes
Lemtrada™ (alemtuzumab) RMS
(1) Homozygous Familial Hypercholesterolemia
(2) Heterozygous Familial Hypercholesterolemia
(3) Venous Thrombo Embolism
(4) Relapsing forms of Multiple Sceloris
(5) Metastatic Colorectal Cancer
CORPORATE PRESENTATION 2011
3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES
Source : IR presentation September 6, 2011
18. Animal health: Merial
18
More than
€2.6 bn
employees worldwide
150countries
production sites
16
in sales in 2010, +2.6%(1)
5,700
With its range
of vaccines
and products to treat
parasites, infection,
inflammation and
ulcers, Merial improves
the health, well-being
and performance
of a large variety
of animals.
(1) Growth at constant exchange rates
Present in more than
CORPORATE PRESENTATION 2011
3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES
Source : annual rewiew 2010
19. Genzyme, a Sanofi company
19CORPORATE PRESENTATION 2011
3. ADAPT THE GROUP TO FUTURE CHALLENGES & OPPORTUNITIES
TodayGlobal leader
in rare genetic diseases
Established,
long-term partnerships
- KOLs,
- Patient groups,
- Health authorities
Technical expertise
across broad range
of technology platforms
Tomorrow
Personalized Genetic Health
Multiple Sclerosis (1)
(1) LemtradaTM (alemtuzumab), AubagioTM (teriflunomide) are brand names for projects currently in development for
which all necessary regulatory authorizations have not been attained.
70
40
sites in more than
in sales in 2010
countries
$1,571m
personalized Genetic Health
Source : annual rewiew 2010, IR presentation September 6, 2011
20. Corporate social responsibility
20
We are a healthcare
company with deep
moral commitments
Acting ethically
and responsibly is part
of our DNA
Giving aid, both in
emergencies and on a daily
basis, means going beyond
our immediate obligations
to protect and serve
as many human beings
as possible.
CORPORATE PRESENTATION 2011
21. Ensuring access to healthcare
21
CORPORATE SOCIAL RESPONSIBILITY
To ensure that the human
right to health becomes
a reality, Sanofi develops
programs to improve
access to medicines
for people in developing
countries
7 disease areas
for Access
to Medicines
Malaria
Tuberculosis
Sleeping sickness
Leishmaniasis
Epilepsy
Mental health
Vaccines
Approach
Information and education,
Medicines adapted to
patients needs,
Tiered pricing policy
R&D program for
therapeutic innovation
CORPORATE PRESENTATION 2011
22. 22
CORPORATE SOCIAL RESPONSIBILITY
Respond
Support
Encourage
Donations in 2010:
boxes of medicines
and
vaccine doses to treat
underprivileged people in
43countriesemployee involvement
development aid
to humanitarian emergencies
974,457
509,218
CORPORATE PRESENTATION 2011
Source : annual rewiew 2010
23. 23
CORPORATE SOCIAL RESPONSIBILITY
HAITI
Bringing access to
healthcare to the population
after the earthquake
FRANCE
Improving medical care for
the homeless
ALGERIA
Diagnosing and socially
rehabilitating children with
mental difficulties
BRESIL
Fighting leishmaniasis
BURUNDI
Training healthcare
professionals.
NEPAL
Fighting infant and maternal
mortality
INDIA
Combining access to
healthcare and mutual
health support
PHILIPPINES
Caring for street childrenTOGO
Fighting Buruli ulcer
TANZANIA
Fighting childhood cancer
Our dedication to healthcare for all: a few examples from around the world
PÉROU
Enhancing access to
healthcare in slums
PERU
CORPORATE PRESENTATION 2011
Source : annual rewiew 2010,
24. Embracing environmental responsibility
24
CORPORATE SOCIAL RESPONSIBILITY
Safeguarding the environment is one
of Sanofi’s responsibilities as a global
healthcare partner. The connection
between environmental hazards
and impact on health has been clearly
established.
Because we are focused on
patients’ needs, reducing
environmental risk is a natural
part of our CSR practices
Carbon footprint and
energy consumption
One of Sanofi’s priority
to reduce its environmental
impact is to control
our carbon footprint
and reduce our energy
consumption.
Since 2005, for every unit
produced, the Group
has decreased direct CO2
emissions by 8 % and indirect
emissions by 17 %.
CORPORATE PRESENTATION 2011
Source : annual rewiew 2010
25. Recommendation
25PRÉSENTATION INSTITUTIONNELLE 2011
This corporate presentation is available for all employees in the Sanofi Group.
It may be used internally or externally for presentations of the Group,
either in whole or in part, as needed.
The information is taken from Information meetings, annual results 2010
and from press releases.
Further information is available on www.sanofi.com
Forward Looking Statements
This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements
are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans,
objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements
regarding future performance. Forward-looking statements are generally identified by the words “expects”, “anticipates”, “believes”, “intends”, “estimates”, “plans”
and similar expressions. Although Sanofi’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are
cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond
the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data
and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device
or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability
or commercial potential of such products candidates, the absence of guarantee that the products candidates if approved will be commercially successful, the future
approval and commercial success of therapeutic alternatives, the Group’s ability to benefit from external growth opportunities as well as those discussed or identified
in the public filings with the SEC and the AMF made by Sanofi, including those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking
Statements” on Form 20-F for the year ended December 31, 2010. Other than as required by applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.
Photography credits : Urbanhearts/Fotolia - Gil Corre - Krzysztof Dydynski/lonely Planet Images/Getty Images - Imagesource V/Fotolia - Gil Corre - Eric Larrayadieu/Interlinks Image - Merial - Julien Chraibi - Gil Corre - Gil Corre (Haïti, Brésil, France, Tanzanie) -
samusocial International (Pérou) - Santé Sud (Algérie) - Jean-Jacques Bernard (Togo) - Chirurgie solidaire (Burundi) - InterAide (Inde) - Stéphane Lehr (Népal) - Virlanie (Philippines) – Getty Images/MIXA
